Stocks · News reference

Cellectar Biosciences shares are trading lower. The company announced it published results from a Phase 1 dose-escalation study evaluating iopofosine I 131 in combination with low-dose dexamethasone in 31 patients with heavily pretreated relapsed/refractory multiple myeloma,

Jul 15, 2026, 11:52 AMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 15, 2026, 11:52 AM
Checked: Jul 15, 2026, 11:52 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 3, 2026, 4:19 PMTim Melvin
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to survive another
ARTV CLRB SGMT VRDN
BenzingaAug 14, 2026, 4:17 PMBenzinga Newsdesk
Cellectar Biosciences 13G Filing Shows Balyasny Asset Management Reports 9.99% Stake In Co As Of June 30, 2026, Holding 798,382 Shares And Warrants
- SEC Filing
CLRB
BenzingaAug 14, 2026, 4:17 PMBenzinga Newsdesk
Cellectar Biosciences 13G Filing Shows StemPoint Capital Reports 9.99% Stake In Co As Of June 30, 2026, Holding 845,740 Shares Including Pre-Funded Warrants
- SEC Filing
CLRB
BenzingaAug 14, 2026, 4:16 PMBenzinga Newsdesk
Cellectar Biosciences 13G Filing Shows SilverArc Capital Reports 9.99% Stake In Co As Of June 30, 2026, Holding 851,285 Shares And Warrants
CLRB